cyc 202 has been researched along with bay 1000394 in 4 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (bay 1000394) | Trials (bay 1000394) | Recent Studies (post-2010) (bay 1000394) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 19 | 2 | 19 |
| Protein | Taxonomy | cyc 202 (IC50) | bay 1000394 (IC50) |
|---|---|---|---|
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | 0.01 | |
| Cyclin-T1 | Homo sapiens (human) | 0.005 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0067 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0101 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.007 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.011 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.0092 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0086 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.163 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.005 | |
| Cyclin-H | Homo sapiens (human) | 0.025 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.025 | |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | 0.007 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.01 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.01 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z | 1 |
| Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C | 1 |
| Duan, Y; Han, J; Hou, S; Liao, C; Wang, Q; Xie, Z; Yang, X | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
4 review(s) available for cyc 202 and bay 1000394
| Article | Year |
|---|---|
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors | 2019 |
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhibitors | 2022 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |